JPWO2019210864A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019210864A5 JPWO2019210864A5 JP2021510509A JP2021510509A JPWO2019210864A5 JP WO2019210864 A5 JPWO2019210864 A5 JP WO2019210864A5 JP 2021510509 A JP2021510509 A JP 2021510509A JP 2021510509 A JP2021510509 A JP 2021510509A JP WO2019210864 A5 JPWO2019210864 A5 JP WO2019210864A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- disease
- methoxyphenyl
- ethoxy
- thieno
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 58
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 30
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 30
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 30
- 201000010099 disease Diseases 0.000 claims 28
- -1 3-ethoxy-4-methoxyphenyl Chemical group 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 24
- 239000013078 crystal Substances 0.000 claims 23
- 238000000634 powder X-ray diffraction Methods 0.000 claims 20
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 claims 10
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 102000004190 Enzymes Human genes 0.000 claims 8
- 108090000790 Enzymes Proteins 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 208000015181 infectious disease Diseases 0.000 claims 6
- 238000002329 infrared spectrum Methods 0.000 claims 6
- 208000011580 syndromic disease Diseases 0.000 claims 6
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 201000004624 Dermatitis Diseases 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 206010040070 Septic Shock Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 238000001914 filtration Methods 0.000 claims 4
- 230000000813 microbial effect Effects 0.000 claims 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 4
- 238000002076 thermal analysis method Methods 0.000 claims 4
- 238000010521 absorption reaction Methods 0.000 claims 3
- 238000000113 differential scanning calorimetry Methods 0.000 claims 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010005949 Bone cancer Diseases 0.000 claims 2
- 208000018084 Bone neoplasm Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 208000004232 Enteritis Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010024229 Leprosy Diseases 0.000 claims 2
- 208000004852 Lung Injury Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 201000009906 Meningitis Diseases 0.000 claims 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 208000025747 Rheumatic disease Diseases 0.000 claims 2
- 208000009125 Sigmoid Neoplasms Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 201000002661 Spondylitis Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 206010043515 Throat cancer Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 206010069363 Traumatic lung injury Diseases 0.000 claims 2
- 208000025865 Ulcer Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 201000005188 adrenal gland cancer Diseases 0.000 claims 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 208000024519 eye neoplasm Diseases 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000010235 heart cancer Diseases 0.000 claims 2
- 208000024348 heart neoplasm Diseases 0.000 claims 2
- 230000000004 hemodynamic effect Effects 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 208000029824 high grade glioma Diseases 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 201000002313 intestinal cancer Diseases 0.000 claims 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 231100000515 lung injury Toxicity 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 201000010453 lymph node cancer Diseases 0.000 claims 2
- 206010025482 malaise Diseases 0.000 claims 2
- 201000011614 malignant glioma Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 201000008106 ocular cancer Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 206010033675 panniculitis Diseases 0.000 claims 2
- 201000001245 periodontitis Diseases 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- 230000000552 rheumatic effect Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 230000036303 septic shock Effects 0.000 claims 2
- 230000001568 sexual effect Effects 0.000 claims 2
- 230000035939 shock Effects 0.000 claims 2
- 201000003825 sigmoid colon cancer Diseases 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 210000004304 subcutaneous tissue Anatomy 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 238000002411 thermogravimetry Methods 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000000706 filtrate Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000001376 precipitating effect Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 238000001757 thermogravimetry curve Methods 0.000 claims 1
Images
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810407741.X | 2018-05-02 | ||
| CN201810407741 | 2018-05-02 | ||
| PCT/CN2019/085327 WO2019210864A1 (zh) | 2018-05-02 | 2019-04-30 | 噻吩衍生物的晶型 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021522348A JP2021522348A (ja) | 2021-08-30 |
| JPWO2019210864A5 true JPWO2019210864A5 (https=) | 2022-05-09 |
| JP2021522348A5 JP2021522348A5 (https=) | 2022-05-09 |
| JP7542523B2 JP7542523B2 (ja) | 2024-08-30 |
Family
ID=68386284
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510510A Pending JP2021523935A (ja) | 2018-05-02 | 2019-04-30 | チオフェン誘導体の固体形態 |
| JP2021510509A Active JP7542523B2 (ja) | 2018-05-02 | 2019-04-30 | チオフェン誘導体の結晶形 |
| JP2020561687A Active JP7481263B2 (ja) | 2018-05-02 | 2019-04-30 | チオフェン誘導体の結晶形 |
| JP2020561683A Active JP7477459B2 (ja) | 2018-05-02 | 2019-04-30 | チオフェン誘導体の結晶形 |
| JP2023204100A Withdrawn JP2024026251A (ja) | 2018-05-02 | 2023-12-01 | チオフェン誘導体の結晶形 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510510A Pending JP2021523935A (ja) | 2018-05-02 | 2019-04-30 | チオフェン誘導体の固体形態 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561687A Active JP7481263B2 (ja) | 2018-05-02 | 2019-04-30 | チオフェン誘導体の結晶形 |
| JP2020561683A Active JP7477459B2 (ja) | 2018-05-02 | 2019-04-30 | チオフェン誘導体の結晶形 |
| JP2023204100A Withdrawn JP2024026251A (ja) | 2018-05-02 | 2023-12-01 | チオフェン誘導体の結晶形 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US11396518B2 (https=) |
| EP (5) | EP3789389B1 (https=) |
| JP (5) | JP2021523935A (https=) |
| KR (4) | KR102839924B1 (https=) |
| CN (7) | CN116813637A (https=) |
| AU (4) | AU2019263865B2 (https=) |
| BR (4) | BR112020021976A2 (https=) |
| CA (4) | CA3213055A1 (https=) |
| DK (1) | DK3789389T3 (https=) |
| ES (1) | ES3047059T3 (https=) |
| FI (1) | FI3789389T3 (https=) |
| PL (1) | PL3789389T3 (https=) |
| PT (1) | PT3789389T (https=) |
| WO (4) | WO2019210864A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116813637A (zh) | 2018-05-02 | 2023-09-29 | 天津合美医药科技有限公司 | 噻吩衍生物的晶型 |
| WO2025103428A1 (zh) * | 2023-11-14 | 2025-05-22 | 赣州和美药业股份有限公司 | 中重度斑块型银屑病的治疗 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| AU2003243153A1 (en) * | 2002-04-23 | 2003-11-10 | Dr. Reddy's Laboratories Limited | Novel crystalline polymorph form-vi of olanzapine and a process for preparation thereof |
| CN101186612B (zh) * | 2006-11-15 | 2012-10-03 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的吡咯啉衍生物及其制备和应用 |
| BRPI1012770B8 (pt) | 2009-05-14 | 2021-05-25 | Tianjin Hemay Bio Tech Co Ltd | derivados de tiofeno |
| WO2012000499A1 (en) | 2010-06-30 | 2012-01-05 | Leo Pharma A/S | New polymorphic form of a calcimimetic compound |
| WO2015082583A1 (en) * | 2013-12-05 | 2015-06-11 | F. Hoffmann-La Roche Ag | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality |
| IL297649A (en) | 2014-07-18 | 2022-12-01 | Green Cross Corp | Crystalline form of 5-chloro-m ({5)-2-oxo-3-[4-(6,5-dihydro-4-[1,2,4]triazin-1yl)phenyl}-1,3- Oxazolidine-5-yl} methyl) thiophene-2-an innovative carboxamide and pharmaceutical preparations containing it |
| EP3144393A1 (en) * | 2015-09-18 | 2017-03-22 | LEK Pharmaceuticals d.d. | A synthetic pathway towards apremilast |
| CN107417626B (zh) * | 2016-05-23 | 2020-01-24 | 江苏奥赛康药业有限公司 | 一种2-氨基嘧啶类化合物的多晶型形式 |
| CN107474057B (zh) * | 2016-06-07 | 2021-03-12 | 天津药物研究院有限公司 | (5-(2-腈基苄基)-4,5,6,7-四氢噻吩并[3,2-c]吡啶-2-基)乙酸酯盐酸盐的晶型及其制备方法和用途 |
| US10570147B2 (en) | 2017-06-13 | 2020-02-25 | Biotheryx, Inc. | Bicyclic compounds and methods of use |
| ES2979170T3 (es) * | 2017-06-30 | 2024-09-24 | Trophy | Aparato de formación de imágenes dentales extraorales con detección de accesorios para el posicionamiento del paciente |
| CN116813637A (zh) * | 2018-05-02 | 2023-09-29 | 天津合美医药科技有限公司 | 噻吩衍生物的晶型 |
-
2019
- 2019-04-30 CN CN202310651520.8A patent/CN116813637A/zh not_active Withdrawn
- 2019-04-30 KR KR1020207034757A patent/KR102839924B1/ko active Active
- 2019-04-30 BR BR112020021976-2A patent/BR112020021976A2/pt unknown
- 2019-04-30 BR BR112020021945-2A patent/BR112020021945A2/pt active Search and Examination
- 2019-04-30 PT PT197971435T patent/PT3789389T/pt unknown
- 2019-04-30 US US17/052,077 patent/US11396518B2/en active Active
- 2019-04-30 FI FIEP19797143.5T patent/FI3789389T3/fi active
- 2019-04-30 AU AU2019263865A patent/AU2019263865B2/en active Active
- 2019-04-30 KR KR1020207034790A patent/KR20210022557A/ko not_active Ceased
- 2019-04-30 ES ES19797143T patent/ES3047059T3/es active Active
- 2019-04-30 AU AU2019262282A patent/AU2019262282B2/en active Active
- 2019-04-30 DK DK19797143.5T patent/DK3789389T3/da active
- 2019-04-30 US US17/052,128 patent/US12227514B2/en active Active
- 2019-04-30 US US17/052,131 patent/US12180222B2/en active Active
- 2019-04-30 JP JP2021510510A patent/JP2021523935A/ja active Pending
- 2019-04-30 CA CA3213055A patent/CA3213055A1/en active Pending
- 2019-04-30 CN CN202310701814.7A patent/CN116836178A/zh active Pending
- 2019-04-30 CN CN201910364512.9A patent/CN110437250B/zh active Active
- 2019-04-30 AU AU2019262284A patent/AU2019262284A1/en not_active Abandoned
- 2019-04-30 CN CN201910365332.2A patent/CN110437251B/zh active Active
- 2019-04-30 WO PCT/CN2019/085327 patent/WO2019210864A1/zh not_active Ceased
- 2019-04-30 WO PCT/CN2019/085360 patent/WO2019210869A1/zh not_active Ceased
- 2019-04-30 PL PL19797143.5T patent/PL3789389T3/pl unknown
- 2019-04-30 CA CA3098931A patent/CA3098931C/en active Active
- 2019-04-30 AU AU2019262286A patent/AU2019262286B2/en active Active
- 2019-04-30 CN CN202310657955.3A patent/CN116947878A/zh active Pending
- 2019-04-30 EP EP19797143.5A patent/EP3789389B1/en active Active
- 2019-04-30 EP EP19796979.3A patent/EP3800190A4/en not_active Withdrawn
- 2019-04-30 CN CN201910364369.3A patent/CN110437249B/zh active Active
- 2019-04-30 EP EP19795994.3A patent/EP3789387B1/en active Active
- 2019-04-30 KR KR1020207033658A patent/KR102686835B1/ko active Active
- 2019-04-30 JP JP2021510509A patent/JP7542523B2/ja active Active
- 2019-04-30 WO PCT/CN2019/085352 patent/WO2019210867A1/zh not_active Ceased
- 2019-04-30 CA CA3098927A patent/CA3098927C/en active Active
- 2019-04-30 BR BR112020022186-4A patent/BR112020022186A2/pt not_active Application Discontinuation
- 2019-04-30 CN CN202310699133.1A patent/CN116854705A/zh active Pending
- 2019-04-30 BR BR112020022190-2A patent/BR112020022190A2/pt active Search and Examination
- 2019-04-30 CA CA3099072A patent/CA3099072A1/en not_active Abandoned
- 2019-04-30 US US17/052,025 patent/US11274104B2/en active Active
- 2019-04-30 WO PCT/CN2019/085342 patent/WO2019210865A1/zh not_active Ceased
- 2019-04-30 JP JP2020561687A patent/JP7481263B2/ja active Active
- 2019-04-30 EP EP24152184.8A patent/EP4335515A3/en not_active Withdrawn
- 2019-04-30 JP JP2020561683A patent/JP7477459B2/ja active Active
- 2019-04-30 KR KR1020207033791A patent/KR102701245B1/ko active Active
- 2019-04-30 EP EP19796726.8A patent/EP3789388B1/en active Active
-
2023
- 2023-12-01 JP JP2023204100A patent/JP2024026251A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102159571B (zh) | 强效hcv抑制剂2-噻唑基-4-喹啉基-氧基衍生物的结晶形式 | |
| CN103998434B (zh) | 作为dhodh抑制剂的噻唑衍生物及其应用 | |
| TWI481604B (zh) | Novel 5-fluorouracil derivatives | |
| CN103539795A (zh) | 阿哌沙班的多晶型及其制备方法 | |
| JP2009537603A (ja) | ５−アミノ−３−（２’，３’−ジ−Ｏ−アセチル−ベータ−Ｄ−リボフラノシル）−３Ｈ−チアゾロ［４，５−ｄ］ピリミジン−２−オンのマレイン酸塩のＡ型及びＢ型結晶形 | |
| AU2018226922B2 (en) | Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof | |
| JP2019516749A5 (https=) | ||
| US20140235633A1 (en) | 4-Aminoquinazoline Derivatives and Uses Thereof | |
| JP2025102940A5 (https=) | ||
| JP6298768B2 (ja) | ７−置換ハンファンギチンｂ誘導体、その調製方法及び使用 | |
| JP2008539278A (ja) | 結晶性ロスバスタチンカルシウム | |
| JPWO2020230028A5 (https=) | ||
| CA2958741C (en) | Quinazoline derivatives | |
| JP2021522348A5 (https=) | ||
| WO2013065063A1 (en) | Anhydrous form of dasatinib, process for its preparation and its use | |
| JPWO2019210864A5 (https=) | ||
| JP2018529769A (ja) | ニコチン酸イノシトールの結晶形ａおよびその製造方法 | |
| FI3789389T3 (fi) | (S)-N-[5-[l-(3-etoksi-4-metoksifenyyli)-2-(metyylisulfonyyli)etyyli]-4,6-diokso-5,6-dihydro-4H-tieno[3,4-c]pyrrol-1-yyli]asetamidin kidemuoto | |
| JP2020524707A (ja) | 塩酸メフパリブの多形体およびその製造方法と使用 | |
| JP2015523349A (ja) | ポリフィリンｉのアシル化誘導体、その調製方法及び使用 | |
| JP6059734B2 (ja) | ２−アルキル−又は２−アリール−置換タンシノン誘導体、その調製方法及び適用 | |
| EP1709033A1 (en) | New polymorphic forms of ondansetron, processes for preparing them, pharmaceutical compositions containing them and their use as antiemetics | |
| JP2021521154A (ja) | 置換ピリジノン含有三環式化合物を調製するための方法 | |
| CN112225730B (zh) | 一种稠环化合物的晶型、其组合物、制备方法及其应用 | |
| JPWO2021050580A5 (https=) |